Skip to main content
SpringerLink
Log in

Overactive Bladder

  • Chapter
  • First Online:
Book cover Principles and Practice of Urogynaecology

  • 1285 Accesses

Abstract

Overactive bladder (OAB) is an umbrella term that includes the symptoms of urinary urgency, frequency, nocturia, and/or urgency incontinence. Prevalence of this condition is reported to be higher in women and also reported to increase with age, with estimates extending up to 40 % after 70 years [1, 2]. OAB has a significant impact upon quality of life [3], as well as having a significant impact on the healthcare system with annual costs ranging from 66 billion US dollars. These costs are related to the routine costs of pads and diapers to patients, as well as the costs associated with the increased risk for falls and fractures, infections, and physical compromise [1]. Asking patients if they suffer these symptoms and tailoring an appropriate and effective treatment regimen is of great value not only for the patient but also for the healthcare system.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    This AUA review does not address the role of β3-agonists.

References

  1. Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014;65:79–95.

    Article  PubMed  Google Scholar 

  2. Coyne KS, Sexton CC, Bell JA, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn. 2013;32:230–7.

    Article  PubMed  Google Scholar 

  3. Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7:455–63.

    Article  PubMed  Google Scholar 

  4. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21:5–26.

    Article  PubMed  Google Scholar 

  5. Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188:2455–63.

    Article  PubMed  Google Scholar 

  6. Burgio KL, Goode PS, Richter HE, Markland AD, Johnson TM, Redden DT. Combined behavioral and individualized drug therapy versus individualized drug therapy alone for urge urinary incontinence in women. J Urol. 2010;184:598–603.

    Article  PubMed  Google Scholar 

  7. Kaya S, Akbayrak T, Beksac S. Comparison of different treatment protocols in the treatment of idiopathic detrusor overactivity: a randomized controlled trial. Clin Rehabil. 2011;25:327–38.

    Article  PubMed  Google Scholar 

  8. Dumoulin C, Hay-Smith J. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev. 2014;5:CD005654.

    Google Scholar 

  9. Subak LL, Johnson C, Whitcomb E, Boban D, Saxton J, Brown JS. Does weight loss improve incontinence in moderately obese women? Int Urogynecol J Pelvic Floor Dysfunct. 2002;13:40–3.

    Article  CAS  PubMed  Google Scholar 

  10. Subak LL, Wing R, West DS, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009;360:481–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F, Kane RL. Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. Ann Intern Med. 2012;156(861–74):W301–10.

    Google Scholar 

  12. Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189:1388–95.

    Article  CAS  PubMed  Google Scholar 

  13. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001;76:358–63.

    Article  CAS  PubMed  Google Scholar 

  14. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004;93:303–10.

    Article  CAS  PubMed  Google Scholar 

  15. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78:687–95.

    Article  CAS  PubMed  Google Scholar 

  16. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005;48:464–70.

    Article  CAS  PubMed  Google Scholar 

  17. Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62:237–42.

    Article  PubMed  Google Scholar 

  18. Goldfischer ER, Sand PK, Thomas H, Peters-Gee J. Efficacy and safety of oxybutynin topical gel 3 % in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2014. doi: 10.1002/nau.22504.

  19. Buser N, Ivic S, Kessler TM, Kessels AG, Bachmann LM. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol. 2012;62:1040–60.

    Article  CAS  PubMed  Google Scholar 

  20. Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63:296–305.

    Article  CAS  PubMed  Google Scholar 

  21. Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomized European-Australian phase 3 trial. Eur Urol. 2013;63:283–95.

    Article  CAS  PubMed  Google Scholar 

  22. Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82:313–20.

    Article  PubMed  Google Scholar 

  23. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164:692–7.

    Article  CAS  PubMed  Google Scholar 

  24. Schmid DM, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol. 2006;176:177–85.

    Article  CAS  PubMed  Google Scholar 

  25. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center randomized double-blind placebo controlled trial. J Urol. 2007;177:2231–6.

    Article  CAS  PubMed  Google Scholar 

  26. Visco AG, Brubaker L, Richter HE, et al. Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial. Contemp Clin Trials. 2012;33:184–96.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinum toxin A for idiopathic overactive bladder: a double-blind placebo controlled randomized dose ranging trial. J Urol. 2010;184:2416–22.

    Article  CAS  PubMed  Google Scholar 

  28. Nitti VW, Dmochowski R, Herschorn S, et al. Onabotulinum toxin A for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189:2186–93.

    Article  CAS  PubMed  Google Scholar 

  29. Chapple C, Sievert KD, MacDiarmid S, et al. Onabotulinum toxin A 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomized, double-blind, placebo-controlled trial. Eur Urol. 2013;64:249–56.

    Article  CAS  PubMed  Google Scholar 

  30. Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol. 2009;181:2608–15.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008;180:217–22.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Zyczynski H for the PFDN. Comparison of cost-effectiveness of onabotulinum toxin A and anticholinergic medications for the treatment of urgency urinary incontinence. Female Pelvic Med Reconstr Surg. 2013;19(5 Suppl):S45–S190.

    Google Scholar 

  33. Tanagho EA, Schmidt RA. Bladder pacemaker: scientific basis and clinical future. Urology. 1982;20:614–9.

    Article  CAS  PubMed  Google Scholar 

  34. Jacobs SA, Lane FL, Osann KE, Noblett KL. Randomized prospective crossover study of interstim lead wire placement with curved versus straight stylet. Neurourol Urodyn. 2014;33(5):488–92.

    Article  PubMed  Google Scholar 

  35. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007;178:2029–34.

    Article  PubMed  Google Scholar 

  36. Siddiqui NY, Wu JM, Amundsen CL. Efficacy and adverse events of sacral nerve stimulation for overactive bladder: a systematic review. Neurourol Urodyn. 2010;29 Suppl 1:S18–23.

    Article  PubMed  Google Scholar 

  37. White WM, Mobley 3rd JD, Doggweiler R, Dobmeyer-Dittrich C, Klein FA. Incidence and predictors of complications with sacral neuromodulation. Urology. 2009;73:731–5.

    Article  PubMed  Google Scholar 

  38. Wexner SD, Hull T, Edden Y, et al. Infection rates in a large investigational trial of sacral nerve stimulation for fecal incontinence. J Gastrointest Surg. 2010;14:1081–9.

    Article  PubMed  Google Scholar 

  39. Spinelli M, Sievert KD. Latest technologic and surgical developments in using InterStim Therapy for sacral neuromodulation: impact on treatment success and safety. Eur Urol. 2008;54:1287–96.

    Article  PubMed  Google Scholar 

  40. Blandon RE, Gebhart JB, Lightner DJ, Klingele CJ. Re-operation rates after permanent sacral nerve stimulation for refractory voiding dysfunction in women. BJU Int. 2008;101:1119–23.

    Article  PubMed  Google Scholar 

  41. Washington BB, Hines BJ. Implant infection after two-stage sacral nerve stimulator placement. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18:1477–80.

    Article  PubMed  Google Scholar 

  42. Amend B, Matzel KE, Abrams P, de Groat WC, Sievert KD. How does neuromodulation work? Neurourol Urodyn. 2011;30:762–5.

    Article  PubMed  Google Scholar 

  43. de Groat WC, Kawatani M. Reorganization of sympathetic preganglionic connections in cat bladder ganglia following parasympathetic denervation. J Physiol. 1989;409:431–49.

    Article  PubMed Central  PubMed  Google Scholar 

  44. Siegel SW, Catanzaro F, Dijkema HE, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology. 2000;56:87–91.

    Article  CAS  PubMed  Google Scholar 

  45. Hassouna MM, Siegel SW, Nyeholt AA, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol. 2000;163:1849–54.

    Article  CAS  PubMed  Google Scholar 

  46. Mellgren A, Wexner SD, Coller JA, et al. Long-term efficacy and safety of sacral nerve stimulation for fecal incontinence. Dis Colon Rectum. 2011;54:1065–75.

    Article  PubMed  Google Scholar 

  47. Hull T, Giese C, Wexner SD, et al. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. Dis Colon Rectum. 2013;56:234–45.

    Article  PubMed  Google Scholar 

  48. Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2014. doi: 10.1002/nau.22544

  49. Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183:1438–43.

    Article  PubMed  Google Scholar 

  50. MacDiarmid SA, Peters KM, Shobeiri SA, et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol. 2010;183:234–40.

    Article  PubMed  Google Scholar 

  51. Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182:1055–61.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynaecology, UC Riverside School of Medicine, University of California, Oakland, CA, USA

    Karen L. Noblett MD

Authors
  1. Karen L. Noblett MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karen L. Noblett MD .

Editor information

Editors and Affiliations

  1. Reproductive Medicine & Women's Health, Chennai, India

    A Tamilselvi

  2. Department of Obstetrics and Gynaecology, James Cook University, Townsville, Australia

    Ajay Rane

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer India

About this chapter

Cite this chapter

Noblett, K.L. (2015). Overactive Bladder. In: Tamilselvi, A., Rane, A. (eds) Principles and Practice of Urogynaecology. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1692-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-81-322-1692-6_6

  • Published:

  • Publisher Name: Springer, New Delhi

  • Print ISBN: 978-81-322-1691-9

  • Online ISBN: 978-81-322-1692-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation